The Future of Laboratory-Developed Tests
Comments on the FDA’s proposed rule to regulate LDTs as in vitro diagnostic devices reveal mixed reactions.
Comments on the FDA’s proposed rule to regulate LDTs as in vitro diagnostic devices reveal mixed reactions.
Debate is underway on whether current CLIA review of LDTs properly assesses a test’s likelihood to detect diseases.
Lab leaders say that the increased level of scrutiny proposed for such tests would be a detriment to innovation and patient care.
The FDA recently submitted its own proposed rule relating to lab-developed test regulation for review.
The agency recently sent its own proposed LDTs regulation rule to the White House Office of Information and Regulatory Affairs for review.